US Patent Issued to Seattle Children's Hospital on April 21 for "IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy" (Washington Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,603, issued on April 21, was assigned to Seattle Children's Hospital (Seattle).

"IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy" was invented by Giacomo Tampella (Seattle), Michael C. Jensen (Seattle) and Adam Johnson (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Some embodiments of the methods and compositions provided herein include cells having membrane-tethered. IL13 mutein-directed zetakine receptors, such as those which specifically bind to the IL-13 receptor alpha 2 (IL13Ra2) at a 50-fold higher affinity than wild-type IL-13, and methods of cell-based immunotherapy targeting cancer cells, such as cells of s...